share_log

康哲藥業：截至二零二三年十二月三十一日止之年度業績公告及建議修訂現有組織章程大綱及細則以及採納新組織章程大綱及細則

CMS: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION

香港交易所 ·  Mar 27 10:40
Summary by Moomoo AI
康哲藥業控股有限公司公佈截至2023年12月31日止年度業績，營業額下降12.4%至人民幣8,013.3百萬元，毛利下降13.2%至人民幣6,109.2百萬元。年度溢利下降27.2%至人民幣2,384.4百萬元，正常化年度溢利下降18.8%至人民幣2,709.3百萬元。公司建議末期股息每股人民幣0.0783元。報告期內，三款創新藥在中國獲批上市，並獲納入國家醫保目錄。此外，公司在東南亞市場取得進展，並完成新加坡生產工廠收購，提升供應鏈和生產能力。公司將繼續聚焦創新產品開發，並加強專科領域商業化平台，以及擴展國際市場業務。
康哲藥業控股有限公司公佈截至2023年12月31日止年度業績，營業額下降12.4%至人民幣8,013.3百萬元，毛利下降13.2%至人民幣6,109.2百萬元。年度溢利下降27.2%至人民幣2,384.4百萬元，正常化年度溢利下降18.8%至人民幣2,709.3百萬元。公司建議末期股息每股人民幣0.0783元。報告期內，三款創新藥在中國獲批上市，並獲納入國家醫保目錄。此外，公司在東南亞市場取得進展，並完成新加坡生產工廠收購，提升供應鏈和生產能力。公司將繼續聚焦創新產品開發，並加強專科領域商業化平台，以及擴展國際市場業務。
CONGE PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, WITH REVENUE DOWN 12.4% TO RMB8,013.3 MILLION AND GROSS PROFIT DOWN 13.2% TO RMB6,109.2 MILLION. Annual profit decreased 27.2% to RMB2,384.4 million and normalized annual profit decreased 18.8% to RMB2,709.3 million. The Company proposes a final dividend of RMB0.0783 per share. During the reporting period, three innovative drugs were approved in China and included in the National Health Insurance Catalog. In addition, the company made progress in the Southeast Asian market and completed the acquisition of a Singapore manufacturing plant, enhancing its supply chain and production capacity. The company will continue to focus on innovative product development and strengthen its specialized commercialization platform, as well as expand its business in international markets.
CONGE PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, WITH REVENUE DOWN 12.4% TO RMB8,013.3 MILLION AND GROSS PROFIT DOWN 13.2% TO RMB6,109.2 MILLION. Annual profit decreased 27.2% to RMB2,384.4 million and normalized annual profit decreased 18.8% to RMB2,709.3 million. The Company proposes a final dividend of RMB0.0783 per share. During the reporting period, three innovative drugs were approved in China and included in the National Health Insurance Catalog. In addition, the company made progress in the Southeast Asian market and completed the acquisition of a Singapore manufacturing plant, enhancing its supply chain and production capacity. The company will continue to focus on innovative product development and strengthen its specialized commercialization platform, as well as expand its business in international markets.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more